Jun 24, 2026 08:00PM
Jun 24, 2026 08:00PM
Jun 21, 2026 08:00PM
Jun 21, 2026 08:00PM
May 31, 2026 08:00PM
May 31, 2026 08:00PM
May 21, 2026 07:49PM 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunothera
May 21, 2026 07:49PM
May 21, 2026 07:49PM
May 10, 2026 08:00PM
Mar 1, 2026 07:00PM
Jan 26, 2026 07:00PM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
Sep 18, 2025 12:00AM
Sep 7, 2025 08:30PM
Sep 7, 2025 08:30PM
Aug 27, 2025 06:08AM
Aug 24, 2025 08:00PM
Aug 24, 2025 08:00PM
Aug 4, 2025 08:00PM Innovent gets FDA approval to test oral diabetes drug IBI3032
Aug 4, 2025 08:00PM
Jul 23, 2025 10:36AM
Jul 16, 2025 08:00PM
Jul 16, 2025 08:00PM
Jul 16, 2025 08:00PM
Jun 30, 2025 12:04AM
Jun 15, 2025 08:00PM Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
Jun 4, 2025 08:23PM
Jun 3, 2025 08:00PM
Jun 2, 2025 09:00PM
Jun 1, 2025 08:00PM
May 31, 2025 09:39PM
Mar 30, 2025 09:19PM
Mar 26, 2025 06:21AM Innovent Announces 2024 Annual Results and Business Updates
Mar 18, 2025 08:57PM
Mar 18, 2025 08:55PM
Mar 2, 2025 07:00PM
Feb 16, 2025 07:00PM
Jan 15, 2025 07:00PM
Jan 2, 2025 07:00PM
Dec 20, 2024 07:10AM Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
Dec 15, 2024 06:57PM
Dec 15, 2024 06:55PM
Dec 8, 2024 07:00PM
Sep 3, 2024 08:00PM
Aug 28, 2024 06:37AM
Jul 5, 2024 04:30AM
Jul 1, 2024 08:00PM Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junctio
Jun 12, 2024 08:00PM

324,033 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All